1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Vistaril® (Hydroxyzine pamoate) capsules

Trade Name: Vistaril(R)
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as antianxiety agent, nausea and vomiting (antiemetic), antihistamine, sedative

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyzine pamoate</td>
<td>10246-75-0</td>
<td>233-582-1</td>
<td>55-60</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Information:</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard gelatin capsules</td>
<td>MIXTURE</td>
<td>Not listed</td>
<td>*</td>
</tr>
</tbody>
</table>

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: 25 mg: Dark green and light green capsule; 50 mg: Green and white capsule; 100 mg: Green and gray capsule

Signal Word: WARNING

Statement of Hazard: May be harmful if swallowed.
Possible risk of harm to the unborn child
May cause central nervous system effects

Additional Hazard Information:
Short Term: May be harmful if swallowed. Accidental ingestion may cause effects similar to those seen in clinical use.
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: The most commonly reported adverse effects seen with the use of hydroxyzine include drowsiness, somnolence, headache, weakness, depression, and irritability.
EU Indication of danger: Harmful
Toxic to Reproduction; Category 3

EU Hazard Symbols: R

EU Risk Phrases: R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Use appropriate ventilation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Storage Conditions: Keep container tightly closed when not in use. Store out of direct sunlight in a well ventilated area at room temperature. Protect from freezing.

Storage Temperature: 15-30°C (59-86°F)

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydroxyzine pamoate
Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Corn Starch
OSHA - Final PELs - TWAs: = 15 mg/m³ TWA total
= 5 mg/m³ TWA

ACGIH Threshold Limit Value (TWA)
Australia TWA = 10 mg/m³ TWA

Sucrose
OSHA - Final PELs - TWAs: = 15 mg/m³ TWA total
= 5 mg/m³ TWA

ACGIH Threshold Limit Value (TWA)
Australia TWA = 10 mg/m³ TWA

Magnesium stearate
ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals
Australia TWA = 10 mg/m³ TWA

Sodium lauryl sulfate
Pfizer OEL TWA-8 Hr: 0.3 mg/m³
Pfizer STEL 0.75 mg/m³

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Good general ventilation should be sufficient to control airborne levels. For laboratory use, handle in a lab fume hood.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES:

<table>
<thead>
<tr>
<th>Physical State</th>
<th>Color</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Dark green/light green; green/white; green/gray</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Molecular Formula</th>
<th>Molecular Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Stability</th>
<th>Conditions to Avoid</th>
<th>Incompatible Materials</th>
<th>Polymerization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable</td>
<td>None known</td>
<td>Strong oxidizers</td>
<td>Will not occur</td>
</tr>
</tbody>
</table>

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

**Magnesium stearate**
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

**Sodium lauryl sulfate**
- Rat Oral LD50 1288 mg/kg

**Sucrose**
- Rat Oral LD50 29.7 g/kg

**Hydroxyzine pamoate**
- Rat Oral LD50 1740 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Inhalation Acute Toxicity: No data available

Ingestion Acute Toxicity: See Acute toxicity table

Irritation / Sensitization: (Study Type, Species, Severity)

**Sodium lauryl sulfate**
- Eye Irritation Rabbit Severe
- Skin Irritation Rabbit Severe
- Eye Irritation / Sensitization No data available
- Skin Irritation / Sensitization No data available

**Chronic Effects/Carcinogenicity**
- No long-term toxicity studies have been conducted to evaluate the chronic toxicity or carcinogenic potential of this material.

Reproductive Effects: No data available
11. TERATOGENICITY

Hydroxyzine when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Hydroxyzine has been associated with teratogenesis in beagle puppies. In pregnant monkeys (one per dose group), oral doses of 6, 8, and 12 mg/kg resulted in abortion in all three pregnancies. However, dosing at 5 or 10 mg/kg did not produce abortions, nor were any gross malformations seen in offspring.

12. MUTAGENICITY

No data available

13. CARCINOGEN STATUS:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

14. AT INCREASE RISK FROM EXPOSURE:

Individuals with a history of hypersensitivity to this material or other materials in its chemical class may be susceptible to the toxicity of overexposure. Individuals taking central nervous system depressants (alcohol, hypnotics, narcotics, barbiturates) should avoid exposure to this material.

15. ADDITIONAL INFORMATION:

FDA PREGNANCY CATEGORY C.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful
Toxic to Reproduction; Category 3

EU Risk Phrases: R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

EU Safety Phrases: S22 - Do not breathe dust.
S36 - Wear suitable protective clothing.
S53 - Avoid exposure - obtain special instructions before use.
WARNING
May be harmful if swallowed.
Possible risk of harm to the unborn child
May cause central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

Hydroxyzine pamoate
Australia (AICS): Present
EU EINECS List 233-582-1

Corn Starch
Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present
EU EINECS List 232-679-6

Sucrose
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS List 200-334-9

Magnesium stearate
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS List 209-150-3

Sodium lauryl sulfate
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS List 205-788-1

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet